108 related articles for article (PubMed ID: 15968107)
1. Genetically engineered myeloma cell vaccine.
Hao S; Chan T; Xiang J
Methods Mol Med; 2005; 113():235-44. PubMed ID: 15968107
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.
Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J
Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063
[TBL] [Abstract][Full Text] [Related]
3. Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells.
Liu Y; Qureshi M; Xiang J
Cancer Biother Radiopharm; 2002 Feb; 17(1):11-8. PubMed ID: 11915168
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma.
Liu Y; Xia D; Li F; Zheng C; Xiang J
Cancer Gene Ther; 2005 Feb; 12(2):122-32. PubMed ID: 15565183
[TBL] [Abstract][Full Text] [Related]
5. Antitumor immunity against bladder cancer induced by ex vivo expression of CD40 ligand gene using retrovirus vector.
Kimura T; Ohashi T; Kikuchi T; Kiyota H; Eto Y; Ohishi Y
Cancer Gene Ther; 2003 Nov; 10(11):833-9. PubMed ID: 14605669
[TBL] [Abstract][Full Text] [Related]
6. Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo.
Yanagi K; Nagayama Y; Nakao K; Saeki A; Matsumoto K; Ichikawa T; Ishikawa H; Hamasaki K; Ishii N; Eguchi K
Int J Oncol; 2003 Feb; 22(2):345-51. PubMed ID: 12527933
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell/myeloma hybrid vaccine.
Xia D; Chan T; Xiang J
Methods Mol Med; 2005; 113():225-33. PubMed ID: 15968106
[TBL] [Abstract][Full Text] [Related]
8. Induction of antitumor immunity by transduction of CD40 ligand gene and interferon-gamma gene into lung cancer.
Noguchi M; Imaizumi K; Kawabe T; Wakayama H; Horio Y; Sekido Y; Hara T; Hashimoto N; Takahashi M; Shimokata K; Hasegawa Y
Cancer Gene Ther; 2001 Jun; 8(6):421-9. PubMed ID: 11498762
[TBL] [Abstract][Full Text] [Related]
9. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C
Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328
[TBL] [Abstract][Full Text] [Related]
10. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma.
Briones J; Timmerman J; Levy R
Cancer Res; 2002 Jun; 62(11):3195-9. PubMed ID: 12036933
[TBL] [Abstract][Full Text] [Related]
11. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity.
Cormary C; Hiver E; Mariamé B; Favre G; Tilkin-Mariamé AF
Cancer Gene Ther; 2005 Dec; 12(12):963-72. PubMed ID: 15956983
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of established tumor growth in syngeneic mice by local inoculation of engineered mouse myeloma cells secreting a recombinant fusion protein RM4/TNF.
Xiang J; Qi Y; Chen Y
Cancer Gene Ther; 1997; 4(6):353-8. PubMed ID: 9408605
[TBL] [Abstract][Full Text] [Related]
13. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
14. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
Dzojic H; Loskog A; Tötterman TH; Essand M
Prostate; 2006 Jun; 66(8):831-8. PubMed ID: 16491482
[TBL] [Abstract][Full Text] [Related]
16. Adeno-associated virus mediated gene transfer into lung cancer cells promoting CD40 ligand-based immunotherapy.
Wu JQ; Zhao WH; Li Y; Zhu B; Yin KS
Virology; 2007 Nov; 368(2):309-16. PubMed ID: 17675129
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells.
Yurkovetsky ZR; Shurin GV; Barry DA; Schuh AC; Shurin MR; Robbins PD
J Gene Med; 2006 Feb; 8(2):129-37. PubMed ID: 16288496
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice.
Ling X; Wang Y; Dietrich MF; Andreeff M; Arlinghaus RB
Oncogene; 2006 Jul; 25(32):4483-90. PubMed ID: 16547503
[TBL] [Abstract][Full Text] [Related]
19. CD40L-transfected myeloma cells transfer prolonged immunity in vivo.
Kim Y; Strehl JW; Sievers E; Gorschlüter M; Brossart P; Schmidt-Wolf IG
In Vivo; 2010; 24(1):45-8. PubMed ID: 20133974
[TBL] [Abstract][Full Text] [Related]
20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
